Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company’s TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global Healthcare Conference. CEO Martin Babler and CFO John Schroer discussed phase III psoriasis results for envudeucitinib, the company’s plans for regulatory filing, a pending phase IIb lupus readout, and development [...]
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead
